394 related articles for article (PubMed ID: 28186287)
1. Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma†.
Ito M; Miyata Y; Yoshiya T; Tsutani Y; Mimura T; Murakami S; Ito H; Nakayama H; Okada M
Eur J Cardiothorac Surg; 2017 Feb; 51(2):218-222. PubMed ID: 28186287
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung.
Kim M; Chung YS; Kim KA; Shim HS
Lung Cancer; 2019 Nov; 137():129-135. PubMed ID: 31586770
[TBL] [Abstract][Full Text] [Related]
3. Distinctive histopathological features of lepidic growth predominant node-negative adenocarcinomas 3-5 cm in size.
Takahashi Y; Ishii G; Aokage K; Hishida T; Yoshida J; Nagai K
Lung Cancer; 2013 Feb; 79(2):118-24. PubMed ID: 23177278
[TBL] [Abstract][Full Text] [Related]
4. Excellent prognosis of lepidic-predominant lung adenocarcinoma: low incidence of lymphatic vessel invasion as a key factor.
Araki K; Kidokoro Y; Hosoya K; Wakahara M; Matsuoka Y; Takagi Y; Haruki T; Miwa K; Taniguchi Y; Horie S; Nakamura H
Anticancer Res; 2014 Jun; 34(6):3153-6. PubMed ID: 24922687
[TBL] [Abstract][Full Text] [Related]
5. Adenocarcinomas with prominent lepidic spread: retrospective review applying new classification of the American Thoracic Society.
Xu L; Tavora F; Battafarano R; Burke A
Am J Surg Pathol; 2012 Feb; 36(2):273-82. PubMed ID: 22198010
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of lung adenocarcinoma second predominant pattern from a large European database.
Bertoglio P; Querzoli G; Ventura L; Aprile V; Cattoni MA; Nachira D; Lococo F; Rodriguez Perez M; Guerrera F; Minervini F; Gnetti L; Bacchin D; Franzi F; Rindi G; Bellafiore S; Femia F; Viti A; Bogina GS; Kestenholz P; Ruffini E; Paci M; Margaritora S; Imperatori AS; Lucchi M; Ampollini L; Terzi AC
J Surg Oncol; 2021 Feb; 123(2):560-569. PubMed ID: 33169397
[TBL] [Abstract][Full Text] [Related]
7. The presence of lepidic and micropapillary/solid pathological patterns as minor components has prognostic value in patients with intermediate-grade invasive lung adenocarcinoma.
Hou Y; Song W; Chen M; Zhang J; Luo Q; Um SW; Facchinetti F; Bongiolatti S; Zhou Q
Transl Lung Cancer Res; 2022 Jan; 11(1):64-74. PubMed ID: 35242628
[TBL] [Abstract][Full Text] [Related]
8. The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma.
Tsutani Y; Miyata Y; Mimae T; Kushitani K; Takeshima Y; Yoshimura M; Okada M
J Thorac Cardiovasc Surg; 2013 Sep; 146(3):580-5. PubMed ID: 23778085
[TBL] [Abstract][Full Text] [Related]
9. Comparison of malignant grade between pure and partially invasive types of early lung adenocarcinoma.
Sasada S; Nakayama H; Miyata Y; Tsubokawa N; Mimae T; Yoshiya T; Murakami S; Ito H; Okada M
Ann Thorac Surg; 2015 Mar; 99(3):956-60. PubMed ID: 25620597
[TBL] [Abstract][Full Text] [Related]
10. Comparison of outcomes following lobectomy, segmentectomy, and wedge resection based on pathological subtyping in patients with pN0 invasive lung adenocarcinoma ≤1 cm.
Song W; Hou Y; Zhang J; Zhou Q
Cancer Med; 2022 Dec; 11(24):4784-4795. PubMed ID: 35570370
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients--based on a hospital study in China.
Song Z; Zhu H; Guo Z; Wu W; Sun W; Zhang Y
Eur J Surg Oncol; 2013 Nov; 39(11):1262-8. PubMed ID: 24063970
[TBL] [Abstract][Full Text] [Related]
12. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Fujimoto M; Kawakami F; Tsuruyama T; Travis WD; Date H; Haga H
J Thorac Oncol; 2013 Jan; 8(1):52-61. PubMed ID: 23242438
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma.
Yoshiya T; Mimae T; Tsutani Y; Tsubokawa N; Sasada S; Miyata Y; Kushitani K; Takeshima Y; Murakami S; Ito H; Nakayama H; Okada M
Ann Thorac Surg; 2016 Nov; 102(5):1668-1673. PubMed ID: 27344277
[TBL] [Abstract][Full Text] [Related]
14. Indications for sublobar resection of clinical stage IA radiologic pure-solid lung adenocarcinoma.
Hattori A; Matsunaga T; Takamochi K; Oh S; Suzuki K
J Thorac Cardiovasc Surg; 2017 Sep; 154(3):1100-1108. PubMed ID: 28629842
[TBL] [Abstract][Full Text] [Related]
15. Acinar-Predominant Pattern Correlates With Poorer Prognosis in Invasive Mucinous Adenocarcinoma of the Lung.
Lin G; Li H; Kuang J; Tang K; Guo Y; Han A; Xie C
Am J Clin Pathol; 2018 Mar; 149(5):373-378. PubMed ID: 29538611
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease.
Kadota K; Villena-Vargas J; Yoshizawa A; Motoi N; Sima CS; Riely GJ; Rusch VW; Adusumilli PS; Travis WD
Am J Surg Pathol; 2014 Apr; 38(4):448-60. PubMed ID: 24472852
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma.
Murakami S; Ito H; Tsubokawa N; Mimae T; Sasada S; Yoshiya T; Miyata Y; Yokose T; Okada M; Nakayama H
Lung Cancer; 2015 Nov; 90(2):199-204. PubMed ID: 26341957
[TBL] [Abstract][Full Text] [Related]
18. Characteristic immunophenotype of solid subtype component in lung adenocarcinoma.
Takuwa T; Ishii G; Nagai K; Yoshida J; Nishimura M; Hishida T; Neri S; Hasegawa S; Ochiai A
Ann Surg Oncol; 2012 Nov; 19(12):3943-52. PubMed ID: 22669454
[TBL] [Abstract][Full Text] [Related]
19. Does the histologic predominance of pathological stage IA lung adenocarcinoma influence the extent of resection?
Ito H; Nakayama H; Murakami S; Yokose T; Katayama K; Miyata Y; Okada M
Gen Thorac Cardiovasc Surg; 2017 Sep; 65(9):512-518. PubMed ID: 28593420
[TBL] [Abstract][Full Text] [Related]
20. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.
Yoshizawa A; Motoi N; Riely GJ; Sima CS; Gerald WL; Kris MG; Park BJ; Rusch VW; Travis WD
Mod Pathol; 2011 May; 24(5):653-64. PubMed ID: 21252858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
